Christine Ring - Nurix Therapeutics G Sec
| NRIX Stock | USD 12.99 0.88 6.34% |
Insider
Christine Ring is G Sec of Nurix Therapeutics
| Age | 59 |
| Phone | 415 660 5320 |
| Web | https://www.nurixtx.com |
Christine Ring Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christine Ring against Nurix Therapeutics stock is an integral part of due diligence when investing in Nurix Therapeutics. Christine Ring insider activity provides valuable insight into whether Nurix Therapeutics is net buyers or sellers over its current business cycle. Note, Nurix Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nurix Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christine Ring over a week ago Acquisition by Christine Ring of 3750 shares of Nurix Therapeutics subject to Rule 16b-3 | ||
Christine Ring over a month ago Disposition of 5537 shares by Christine Ring of Nurix Therapeutics at 1.86 subject to Rule 16b-3 | ||
Christine Ring over two months ago Disposition of 5760 shares by Christine Ring of Nurix Therapeutics at 19.4956 subject to Rule 16b-3 | ||
Christine Ring over three months ago Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3 |
Nurix Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2598) % which means that it has lost $0.2598 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5322) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics' management efficiency ratios could be used to measure how well Nurix Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Abhinav Shukla | Shattuck Labs | ||
| John Castle | Monte Rosa Therapeutics | 54 | |
| Ben Strain | Foghorn Therapeutics | N/A | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| Matthew Stanton | Generation Bio Co | 52 | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| MBA MD | Generation Bio Co | 55 | |
| James Trager | Nkarta Inc | 61 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Richard MD | Lyell Immunopharma | 73 | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| Christopher Roberts | Black Diamond Therapeutics | 54 | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Erin JD | Shattuck Labs | 44 | |
| David Epstein | Black Diamond Therapeutics | 66 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Crystal MD | Lyell Immunopharma | 64 | |
| Mark Angelino | Generation Bio Co | 52 | |
Management Performance
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.26 |
Nurix Therapeutics Leadership Team
Elected by the shareholders, the Nurix Therapeutics' board of directors comprises two types of representatives: Nurix Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nurix. The board's role is to monitor Nurix Therapeutics' management team and ensure that shareholders' interests are well served. Nurix Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nurix Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefani Wolff, COO Devel | ||
| Christopher Phelps, Senior Discovery | ||
| Arthur MD, Founder Board | ||
| Christine JD, Secretary Officer | ||
| John Kuriyan, Founder Board | ||
| JD Esq, VP Counsel | ||
| Cristiana Guiducci, Senior Research | ||
| Pasit Phiasivongsa, Chief Officer | ||
| Pr MD, Founder Board | ||
| Rita Kwong, Accounting Mang | ||
| Johannes Houte, Chief Officer | ||
| Christine Ring, G Sec | ||
| Gwenn Hansen, Chief Officer | ||
| Eric JD, Chief Officer | ||
| Michael Rap, Founder Board | ||
| Jason Kantor, Chief Officer |
Nurix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nurix Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (4.87) % | ||||
| Current Valuation | 473.55 M | ||||
| Shares Outstanding | 75.89 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 98.64 % | ||||
| Number Of Shares Shorted | 11.36 M | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 19.30 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.